{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T01:08:26Z","timestamp":1778548106964,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8,14]]},"DOI":"10.7759\/cureus.90054","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T09:34:36Z","timestamp":1755164076000},"source":"Crossref","is-referenced-by-count":1,"title":["Trends in Glucagon-Like Peptide-1 Agonist Use and BMI Among Obese Adults With Type 2 Diabetes: Analysis of the 2010-2015 National Ambulatory Medical Care Survey (NAMCS), Adjusted for Cardiovascular Comorbidity"],"prefix":"10.7759","author":[{"given":"Victoria","family":"Eneh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naomi F","family":"Chatelain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Okelue E","family":"Okobi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Efeturi M","family":"Okorigba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugochukwu  P","family":"Chukwuebuni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tochukwu W","family":"Okahia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita  A","family":"Bampoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edamisan J","family":"Fanegan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chioma  C","family":"Ubajaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adebola Y","family":"Afolayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sunday  O","family":"Arifayan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ijeoma","family":"Kenechukwu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14313","article-title":"Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US","volume":"20","author":"Wang W","year":"2024","unstructured":"Wang W, Wang Q, Qi X, et al.. Associations of semaglutide with first-time diagnosis of Alzheimer's disease in patients with type 2 diabetes: target trial emulation using nationwide real-world data in the US. Alzheimers Dement. 2024, 20:8661-72. 10.1002\/alz.14313","journal-title":"Alzheimers Dement"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.2337\/dc16-2099","article-title":"A national effort to prevent type 2 diabetes: participant-level evaluation of CDC's national diabetes prevention program","volume":"40","author":"Ely EK","year":"2017","unstructured":"Ely EK, Gruss SM, Luman ET, et al.. A national effort to prevent type 2 diabetes: participant-level evaluation of CDC's national diabetes prevention program. Diabetes Care. 2017, 40:1331-41. 10.2337\/dc16-2099","journal-title":"Diabetes Care"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/nu15214671","article-title":"Regulation of macronutrients in insulin resistance and glucose homeostasis during type 2 diabetes mellitus","volume":"15","author":"Yang W","year":"2023","unstructured":"Yang W, Jiang W, Guo S. Regulation of macronutrients in insulin resistance and glucose homeostasis during type 2 diabetes mellitus. Nutrients. 2023, 15:4671. 10.3390\/nu15214671","journal-title":"Nutrients"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2337\/dc20-2926","article-title":"Trends in first-line glucose-lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA","volume":"44","author":"Shin H","year":"2021","unstructured":"Shin H, Schneeweiss S, Glynn RJ, Patorno E. Trends in first-line glucose-lowering drug use in adults with type 2 diabetes in light of emerging evidence for SGLT-2i and GLP-1RA. Diabetes Care. 2021, 44:1774-82. 10.2337\/dc20-2926","journal-title":"Diabetes Care"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15462","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits\u2014the role of the GLP-1 receptor","volume":"179","author":"Helmst\u00e4dter J","year":"2022","unstructured":"Helmst\u00e4dter J, Keppeler K, K\u00fcster L, M\u00fcnzel T, Daiber A, Steven S. Glucagon-like peptide-1 (GLP-1) receptor agonists and their cardiovascular benefits\u2014the role of the GLP-1 receptor. Br J Pharmacol. 2022, 179:659-76. 10.1111\/bph.15462","journal-title":"Br J Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106550","article-title":"Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment","volume":"186","author":"Kopp KO","year":"2022","unstructured":"Kopp KO, Glotfelty EJ, Li Y, Greig NH. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: implications for neurodegenerative disease treatment. Pharmacol Res. 2022, 186:106550. 10.1016\/j.phrs.2022.106550","journal-title":"Pharmacol Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/4020492","article-title":"GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes","volume":"2018","author":"Del Olmo-Garcia MI","year":"2018","unstructured":"Del Olmo-Garcia MI, Merino-Torres JF. GLP-1 receptor agonists and cardiovascular disease in patients with type 2 diabetes. J Diabetes Res. 2018, 2018:4020492. 10.1155\/2018\/4020492","journal-title":"J Diabetes Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2337\/db14-1052","article-title":"Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production","volume":"64","author":"Jun LS","year":"2015","unstructured":"Jun LS, Millican RL, Hawkins ED, et al.. Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production. Diabetes. 2015, 64:819-27. 10.2337\/db14-1052","journal-title":"Diabetes"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2023.07.010","article-title":"GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss\u2014chemistry, physiology, and clinical applications","volume":"35","author":"Campbell JE","year":"2023","unstructured":"Campbell JE, M\u00fcller TD, Finan B, DiMarchi RD, Tsch\u00f6p MH, D'Alessio DA. GIPR\/GLP-1R dual agonist therapies for diabetes and weight loss\u2014chemistry, physiology, and clinical applications. Cell Metab. 2023, 35:1519-29. 10.1016\/j.cmet.2023.07.010","journal-title":"Cell Metab"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction","volume":"21","author":"Nauck MA","year":"2022","unstructured":"Nauck MA, D'Alessio DA. Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction. Cardiovasc Diabetol. 2022, 21:169. 10.1186\/s12933-022-01604-7","journal-title":"Cardiovasc Diabetol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.176351","article-title":"Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future","volume":"20","author":"Kalra S","year":"2016","unstructured":"Kalra S, Baruah MP, Sahay RK, Unnikrishnan AG, Uppal S, Adetunji O. Glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes: past, present, and future. Indian J Endocrinol Metab. 2016, 20:254-67. 10.4103\/2230-8210.176351","journal-title":"Indian J Endocrinol Metab"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-55524-w","article-title":"Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis","volume":"9","author":"Castellana M","year":"2019","unstructured":"Castellana M, Cignarelli A, Brescia F, Perrini S, Natalicchio A, Laviola L, Giorgino F. Efficacy and safety of GLP-1 receptor agonists as add-on to SGLT2 inhibitors in type 2 diabetes mellitus: a meta-analysis. Sci Rep. 2019, 9:19351. 10.1038\/s41598-019-55524-w","journal-title":"Sci Rep"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015323","article-title":"Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: a meta-analysis","volume":"9","author":"Hu M","year":"2020","unstructured":"Hu M, Cai X, Yang W, Zhang S, Nie L, Ji L. Effect of hemoglobin A1c reduction or weight reduction on blood pressure in glucagon-like peptide-1 receptor agonist and sodium-glucose cotransporter-2 inhibitor treatment in type 2 diabetes mellitus: a meta-analysis. J Am Heart Assoc. 2020, 9:e015323. 10.1161\/JAHA.119.015323","journal-title":"J Am Heart Assoc"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S216054","article-title":"Long-acting injectable GLP-1 receptor agonists for the treatment of adults with type 2 diabetes: perspectives from clinical practice","volume":"13","author":"Morieri ML","year":"2020","unstructured":"Morieri ML, Avogaro A, Fadini GP. Long-acting injectable GLP-1 receptor agonists for the treatment of adults with type 2 diabetes: perspectives from clinical practice. Diabetes Metab Syndr Obes. 2020, 13:4221-34. 10.2147\/DMSO.S216054","journal-title":"Diabetes Metab Syndr Obes"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212117","article-title":"Racial and ethnic disparities in medication adherence among privately insured patients in the United States","volume":"14","author":"Xie Z","year":"2019","unstructured":"Xie Z, St Clair P, Goldman DP, Joyce G. Racial and ethnic disparities in medication adherence among privately insured patients in the United States. PLoS ONE. 2019, 14:e0212117. 10.1371\/journal.pone.0212117","journal-title":"PLoS ONE"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.119.005600","article-title":"Racial, ethnic, and socioeconomic inequities in the prescription of direct oral anticoagulants in patients with venous thromboembolism in the United States","volume":"12","author":"Nathan AS","year":"2019","unstructured":"Nathan AS, Geng Z, Dayoub EJ, et al.. Racial, ethnic, and socioeconomic inequities in the prescription of direct oral anticoagulants in patients with venous thromboembolism in the United States. Circ Cardiovasc Qual Outcomes. 2019, 12:e005600. 10.1161\/CIRCOUTCOMES.119.005600","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.059595","article-title":"GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes","volume":"146","author":"Marx N","year":"2022","unstructured":"Marx N, Husain M, Lehrke M, Verma S, Sattar N. GLP-1 receptor agonists for the reduction of atherosclerotic cardiovascular risk in patients with type 2 diabetes. Circulation. 2022, 146:1882-94. 10.1161\/CIRCULATIONAHA.122.059595","journal-title":"Circulation"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-019-04843-9","article-title":"Primary care provides the majority of outpatient care for patients with diabetes in the US: NAMCS 2009-2015","volume":"34","author":"Pilla SJ","year":"2019","unstructured":"Pilla SJ, Segal JB, Maruthur NM. Primary care provides the majority of outpatient care for patients with diabetes in the US: NAMCS 2009-2015. J Gen Intern Med. 2019, 34:1089-91. 10.1007\/s11606-019-04843-9","journal-title":"J Gen Intern Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.obpill.2022.100045","article-title":"Weight-centric treatment of type 2 diabetes mellitus","volume":"4","author":"Ghusn W","year":"2022","unstructured":"Ghusn W, Hurtado MD, Acosta A. Weight-centric treatment of type 2 diabetes mellitus. Obes Pillars. 2022, 4:100045. 10.1016\/j.obpill.2022.100045","journal-title":"Obes Pillars"},{"key":"ref20","unstructured":"National Hospital Ambulatory Medical Care Survey. Accessed. July 17, 2025: https:\/\/ftp.cdc.gov\/pub\/Health_Statistics\/NCHS\/Dataset_Documentation\/NAMCS\/stata\/."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2015.07.015","article-title":"Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis","volume":"110","author":"Sun F","year":"2015","unstructured":"Sun F, Wu S, Guo S, et al.. Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: a systematic review and network meta-analysis. Diabetes Res Clin Pract. 2015, 110:26-37. 10.1016\/j.diabres.2015.07.015","journal-title":"Diabetes Res Clin Pract"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60659-0","article-title":"Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)","volume":"374","author":"Buse JB","year":"2009","unstructured":"Buse JB, Rosenstock J, Sesti G, et\u00a0al.. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet. 2009, 374:39-47. 10.1016\/S0140-6736(09)60659-0","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1038\/ajh.2009.245","article-title":"Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes","volume":"23","author":"Okerson T","year":"2010","unstructured":"Okerson T, Yan P, Stonehouse A, Brodows R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. Am J Hypertens. 2010, 23:334-9. 10.1038\/ajh.2009.245","journal-title":"Am J Hypertens"},{"key":"ref24","article-title":"Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes, Diabetologia","volume":"52","author":"Plutzky J","year":"2009","unstructured":"Plutzky J, Garber A, Toft A, D, Poulter NR. Meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes, Diabetologia. Diabetologia. 2009, 52:299.","journal-title":"Diabetologia"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/397847-trends-in-glucagon-like-peptide-1-agonist-use-and-bmi-among-obese-adults-with-type-2-diabetes-analysis-of-the-2010-2015-national-ambulatory-medical-care-survey-namcs-adjusted-for-cardiovascular-comorbidity","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T09:34:37Z","timestamp":1755164077000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/397847-trends-in-glucagon-like-peptide-1-agonist-use-and-bmi-among-obese-adults-with-type-2-diabetes-analysis-of-the-2010-2015-national-ambulatory-medical-care-survey-namcs-adjusted-for-cardiovascular-comorbidity"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.90054","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}